NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Amylyx Pharmaceuticals, Inc. (AMLX) Stock Analysis

Amylyx Pharmaceuticals, Inc. (AMLX) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AMLX

$29.03

+$0.26 (+0.90%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMLX with… →

AMLX Key Statistics

As of Oct 21, 2026
Trading
Open
$28.96
Previous Close
$28.77
Day's Range
28.81–29.78
52-Week Range
10.83–41.14
Volume
1.63M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.09
Valuation
Market Cap
$3.64B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.41
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$144.74M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
125.51M
1-Year Return
+89.86%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
2.32M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AMLX closed at $29.03, +89.86% over 1 year.

Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $3.64B.

In fiscal 2025, AMLX reported revenue of $0.00.

AMLX Stock Return by Calendar Year

Amylyx Pharmaceuticals, Inc. (AMLX) return since Jan 2022: what $10,000 became

1 year
$10,000 $18,986
+89.86%
3 years
$10,000 $17,239
+72.39%
Since Jan 2022
$10,000 $16,065
+60.65%

If you had invested $10,000 in Amylyx Pharmaceuticals, Inc. (AMLX) at the close on January 7, 2022, the earliest close on record here, it would have been worth $16,065 at the close on October 21, 2026: +60.65% in total, +10.41% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+140.31%
2025+219.58%
2024−74.32%
2023−60.16%
2022+104.48%

As of October 21, 2026.

AMLX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$144.74M—
2024$87.37M−$301.74M−345.4%
2023$380.79M$49.27M12.9%
2022$22.23M−$198.38M−892.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$153.29M−$144.74M—
2024$87.37M−$37.26M−$255.68M−$301.74M−345.4%
2023$380.79M$355.35M$38.80M$49.27M12.9%
2022$22.23M$19.24M−$201.34M−$198.38M−892.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amylyx Pharmaceuticals, Inc. (AMLX) carries a market capitalisation of $3.64B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 136.

The most recent close on file for AMLX is $29.03, dated October 21, 2026. That is +$0.26 (+0.90%) against the previous close. The 52-week range on file runs from $10.83 to $41.14. The latest close sits 168.05% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $87.37M, that is a change of −100.00%. The same year closed with a net loss of $144.74M. Earnings per share on a trailing basis come to −1.41.

Across the 4 fiscal years on file, revenue moves from $22.23M in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is −0.09. Daily returns over the trailing 4 years annualize to a volatility of 85.17%. Over the trailing twelve months the total return is +89.86%. Across 3 years the annualized return works out at +19.90%.

Growth & Income

No dividend is on file for AMLX.

Across the complete calendar years on file, 2025 returned +219.58% and 2024 returned −74.32%. Of the 4 complete calendar years on file, 2 finished higher. 2026 is still running; the total return is +140.31% year to date.

Peer Comparison

Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amylyx Pharmaceuticals, Inc. AMLX $3.64B —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Amylyx Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Visit website →